About: Biolex     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/c/7wKN4mfqfc

Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina which was founded in 1997 and raised $190 million from investors. It filed for Chapter 7 bankruptcy on July 5, 2012.

AttributesValues
rdf:type
rdfs:label
  • Biolex (en)
rdfs:comment
  • Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina which was founded in 1997 and raised $190 million from investors. It filed for Chapter 7 bankruptcy on July 5, 2012. (en)
foaf:homepage
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Biolex_Logo.gif
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
thumbnail
has abstract
  • Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina which was founded in 1997 and raised $190 million from investors. It filed for Chapter 7 bankruptcy on July 5, 2012. The company focused on expression of difficult-to-synthesize recombinant proteins in its LEX platform, which used Lemna, a duckweed. The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna. Therapeutic glycosylated proteins, including monoclonal antibodies and interferon (IFN-alpha2b) have been produced using the LEX platform. Biolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired the LemnaGene SA of Lyon, France in 2005. Biolex was a privately held company, originally backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners. The term "plantibody" is trademarked by Biolex. In May 2012 Biolex announced that it sold the LEX System to Synthon, a Netherlands-based specialty pharmaceutical company. The sale included two preclinical biologics made with the LEX System, BLX-301, a humanized and glyco-optimized anti-CD20 antibody for non-Hodgkin's B-cell lymphoma and other B-cell malignancies and BLX-155, a direct-acting thrombolytic. The financial terms of the sale were not disclosed. (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git147 as of Sep 06 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software